Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon, Steven De Vleeschouwer(KU Leuven), Maria Dêbiec‐Rychter(Center for Human Genetics), Frank Van Calenbergh(Universitair Ziekenhuis Leuven), Steffen Fieuws(Statistics Belgium), Johan Menten(Catholic University of America), Tina Verschuere(KU Leuven), Philippe Demaerel(KU Leuven), Guido Wilms(Ospedale “M. Bufalini” di Cesena), Raf Sciot(KU Leuven), Jan Goffin(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Stefaan W. Van Gool(KU Leuven), Wim Maes(KU Leuven)
Cited by 162
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573